Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / Kelun-Biotech sac-TMT Phase III Results
Tech clinical trial results

Kelun-Biotech sac-TMT Phase III Results

Analysis based on 14 articles · First reported May 30, 2026 · Last updated May 31, 2026

Sentiment
70
Attention
6
Articles
14
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive Phase III clinical trial results for sac-TMT are expected to significantly boost the stock price and market valuation of Sichuan Kelun-Biotech Biopharmaceutical>>>. For Merck & Co.>>>, the validation of sac-TMT in combination with KEYTRUDA strengthens its oncology pipeline and future revenue potential, positively impacting its market sentiment.

Biotechnology Pharmaceuticals
Event Summary

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced positive results from its Phase III OptiTROP-Lung05 clinical study for sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab (KEYTRUDA) as a first-line treatment for non-small cell lung cancer (NSCLC). The study demonstrated statistically significant and clinically meaningful benefits in progression-free survival and showed a positive trend in overall survival. These findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet. Sac-TMT, a core product of Sichuan Kelun-Biotech Biopharmaceutical>>>, is a novel TROP2 ADC. Merck & Co.>>> holds exclusive rights to develop and commercialize sac-TMT outside Greater China. The China — National Medical Products Administration>>> in China>>> has also accepted a new indication application for sac-TMT for priority review.

Key Actions
100 Sichuan Kelun-Biotech Biopharmaceutical announced results
70 Sichuan Kelun-Biotech Biopharmaceutical licensed rights Merck & Co.
60 China — National Medical Products Administration accepted application Sichuan Kelun-Biotech Biopharmaceutical
40 American Society of Clinical Oncology selected findings for presentation
Entities Involved
priv
Sichuan Kelun-Biotech Biopharmaceutical
The company announced positive Phase III clinical trial results for sac-TMT, a core product, which significantly prolonged progression-free survival in NSCLC patients. This enhances its product pipeline and market position.
Importance 100 Sentiment 75
stock
Merck & Co.
As the licensee for sac-TMT outside Greater China, the positive clinical trial results for sac-TMT in combination with its drug pembrolizumab (KEYTRUDA) validate its investment and expand its oncology portfolio.
Importance 80 Sentiment 60
ngo
American Society of Clinical Oncology
The organization hosted the annual meeting where the Phase III clinical study results were presented as an oral presentation, providing a platform for dissemination of the findings.
Importance 40 Sentiment 0
per
Caicun Zhou
Professor Caicun Zhou presented the positive results of the OptiTROP-Lung05 study, highlighting its potential to bring new treatment options for lung cancer patients.
Importance 30 Sentiment 0
govactor
China — National Medical Products Administration
The agency has granted sac-TMT six Breakthrough Therapy Designations and accepted a new indication application for review, indicating regulatory recognition of the drug's potential.
Importance 20 Sentiment 0
cnt
China
Sac-TMT has multiple indications approved and marketed in China, with two included in the National Reimbursement Drug List, benefiting patients in the country.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.